163 related articles for article (PubMed ID: 11772238)
21. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
[TBL] [Abstract][Full Text] [Related]
22. Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.
Wu J; Yu E
Cancer Metastasis Rev; 2014 Sep; 33(2-3):607-17. PubMed ID: 24414227
[TBL] [Abstract][Full Text] [Related]
23. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
24. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
25. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor signaling in androgen-refractory prostate cancer.
Grossmann ME; Huang H; Tindall DJ
J Natl Cancer Inst; 2001 Nov; 93(22):1687-97. PubMed ID: 11717329
[TBL] [Abstract][Full Text] [Related]
27. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer.
Griffiths K; Morton MS; Nicholson RI
Eur Urol; 1997; 32 Suppl 3():24-40. PubMed ID: 9267783
[TBL] [Abstract][Full Text] [Related]
28. Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells.
Ketola K; Vainio P; Fey V; Kallioniemi O; Iljin K
Mol Cancer Ther; 2010 Dec; 9(12):3175-85. PubMed ID: 21159605
[TBL] [Abstract][Full Text] [Related]
29. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
Nguyen MM; Wang Z
Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
[TBL] [Abstract][Full Text] [Related]
30. Effect of zinc on regulation of insulin-like growth factor signaling in human androgen-independent prostate cancer cells.
Banudevi S; Senthilkumar K; Sharmila G; Arunkumar R; Vijayababu MR; Arunakaran J
Clin Chim Acta; 2010 Feb; 411(3-4):172-8. PubMed ID: 19913001
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
32. Management of hormone-sensitive metastatic prostate cancer.
Agarwal N; Hussain M
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1221-41, viii. PubMed ID: 24188260
[TBL] [Abstract][Full Text] [Related]
33. Hormone treatment for prostate cancer: current issues and future directions.
Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
[TBL] [Abstract][Full Text] [Related]
34. Mechanistic concepts in androgen-dependence of prostate cancer.
Craft N; Sawyers CL
Cancer Metastasis Rev; 1998-1999; 17(4):421-7. PubMed ID: 10453286
[TBL] [Abstract][Full Text] [Related]
35. Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.
Hofer MD
Fundam Clin Pharmacol; 2018 Oct; 32(5):547. PubMed ID: 30209857
[No Abstract] [Full Text] [Related]
36. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H
Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959
[TBL] [Abstract][Full Text] [Related]
37. Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin.
Sharma V; Kumar L; Mohanty SK; Maikhuri JP; Rajender S; Gupta G
Mol Cell Endocrinol; 2016 Aug; 431():12-23. PubMed ID: 27132804
[TBL] [Abstract][Full Text] [Related]
38. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens.
Granchi S; Brocchi S; Bonaccorsi L; Baldi E; Vinci MC; Forti G; Serio M; Maggi M
Prostate; 2001 Dec; 49(4):267-77. PubMed ID: 11746273
[TBL] [Abstract][Full Text] [Related]
39. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.
Krueckl SL; Sikes RA; Edlund NM; Bell RH; Hurtado-Coll A; Fazli L; Gleave ME; Cox ME
Cancer Res; 2004 Dec; 64(23):8620-9. PubMed ID: 15574769
[TBL] [Abstract][Full Text] [Related]
40. Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide.
Tong da Y; Wen XQ; Jin Y; Liu ZW; Sun HY; Zhou FJ; Wu XY
Asian Pac J Cancer Prev; 2010; 11(6):1805-9. PubMed ID: 21338237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]